Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 34% Improvement Relative Risk HCQ+AZ 56% c19hcq.org D'Arminio Monforte et al. HCQ LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 539 patients in Italy Lower mortality with HCQ (not stat. sig., p=0.12) D'Arminio Monforte et al., Int. J. Infectious Di.., doi:10.1016/j.ijid.2020.07.056 Favors HCQ Favors control
Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?
D'Arminio Monforte et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.07.056
D'Arminio Monforte et al., Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?, Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.07.056
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
HCQ+AZ adjusted death HR 0.44, p=0.009. Propensity scores include baseline COVID-19 disease severity, age, gender, number of comorbidities, cardio-vascular disease, duration of symptoms, date of admission, baseline plasma CRP. IPW censoring. Retrospective study of 539 COVID-19 hospitalized patients in Milan, with treatment a median of 1 day after admission. HCQ 197 patients, HCQ+AZ 94, control 92. Control group received various other treatments. Authors excluded people receiving other drugs which could have biased the effect of HCQ when used in combination. Residual confounding is possible (e.g., people with CVD were more frequent in control), however people in the control group were more likely to require mechanical ventilation.
risk of death, 34.0% lower, HR 0.66, p = 0.12, treatment 53 of 197 (26.9%), control 47 of 92 (51.1%), NNT 4.1, adjusted per study.
HCQ+AZ, 56.0% lower, HR 0.44, p = 0.009, treatment 22 of 94 (23.4%), control 47 of 92 (51.1%), NNT 3.6, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
D'Arminio Monforte et al., 29 Jul 2020, retrospective, Italy, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Infectious Diseases 99 (2020) 75–76 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Letter to the Editor Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal? Dear Sir, Arshad et al. show evidence for reduced mortality in COVID-19 patients taking hydroxychloroquine alone or with azithromycin in an observational study in the USA (Arshad et al., 2020). Data on the effectiveness and toxicity of hydroxychloroquine are controversial (Liu et al., 2020; Devaux et al., 2020; Gautret et al., 2020; Tang et al., 2020; Geleris et al., 2020). A total of 539 COVID-19 hospitalized patients were included in our cohort in Milan, from February 24 to May 17, 2020, of whom 174 died in hospital (day 14 probability of death: 29.5% – 95%CI: 25.5–34.0). We divided a subset of our cohort into three groups who started treatment a median of 1 day after admission: those receiving hydroxychloroquine alone (N = 197), those receiving hydroxycholoroquine + azithromycin (N = 94), and those receiving neither (controls) (N = 92). Of the latter group, ten started HIV antivirals (boosted-lopinavir or –darunavir), one teicoplanin, twelve immunomodulatory drugs, or corticosteroids, 23 heparin and 46 remained untreated. The percent of death in the three groups was 27%, 23%, and 51%. Mechanical ventilation was used in 4.3% of hydroxychloroquine, 14.2% of hydroxychloroquine + azithromycin, and 26.1% of controls. Unweighted and weighted relative hazards of mortality are shown in Table 1. After adjusting for several key confounders (see table), the use of hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested more substantial effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease (PO2/FiO2 > 300, interaction p-value <0.0001). Our results are remarkably similar to those shown by Arshad et al. Some important weaknesses in Arshad et al.’s analysis have been pointed out (Lee et al., 2020), but not all of these apply to our study. Our propensity scores include some of the potential confounders that were missing in the analysis by Arshad (e.g., calendar day of admission, disease severity, cardiovascular disease (CVD), baseline plasma CRP); second, we have excluded people receiving other drugs which could have biased the effect of hydroxychloroquine when used in combination. Third, although residual confounding is a possibility (e.g., people with CVD were more frequent in control), people in the control group were more likely to undergo mechanical ventilation, which is a conservative bias. These results from two different real-life settings (Italy and USA), conflict with those of two large randomized trials (Horby et al., 2020; World Health Organization, 2020). Although unmeasured confounding remains the most likely explanation for the discrepancies, a robust meta-analysis is still lacking, and we believe that hydroxychloroquine should be further tested in randomised trials. When best to start treatment is also a question that needs to be addressed in ad-hoc randomized studies. Table 1 Unadjusted and adjusted marginal relative hazards of in-hospital mortality Unadjusted HR (95% CI) Control# (n = 92) Hydroxychloroquine (n = 197) Hydroxychloroquine + Azithromycin (n = 94) Control# (n = 41) Hydroxychloroquine (n = 83) Hydroxychloroquine +..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit